Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol and doxycycline for Parkinson's disease
ACTRN12623000843651Phase 2Not yet recruiting
- Sponsor
- University of Sydney
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ambroxol and doxycycline in Parkinson's disease (PD) (4 arms), sponsored by University of Sydney. Primary endpoint: Change in motor symptoms measured by the MDS-UPDRS. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
ambroxoldoxycycline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12623000843651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000843651.